<h2 data-pm-slice="">IVIG Market Analysis: Rising Demand to Drive USD 21.06 Billion Valuation by 2030</h2>
<p data-pm-slice="">The <strong>global <a href="https://straitsresearch.com/report/intravenous-immunoglobulin-market">Intravenous Immunoglobulin Market</a></strong>&nbsp;was valued at <strong>USD 11.17 billion</strong> in <strong>2021</strong> and is projected to grow from <strong>USD XX billion</strong> in <strong>2022</strong> to <strong>USD 21.06 billion</strong> by <strong>2030</strong>, at a <strong>CAGR of 7.3%</strong> during the forecast period <strong>(2022&ndash;2030).</strong></p>
<img src="https://bresdel.com/content/uploads/photos/2025/02/bresdel_32a424f9f3c6f2835b12eef257f560fa.jpg">
<h3>Market Catalysts for Expansion</h3>
<p>The growth of the <strong>Intravenous Immunoglobulin (IVIG) Market</strong> is driven by the rising prevalence of <strong>immunodeficiency disorders</strong>, increased awareness of <strong>IVIG therapy</strong>, and technological advancements in plasma-derived products. The growing geriatric population, which is more susceptible to immune system disorders, along with an increasing number of <strong>FDA approvals</strong> for IVIG therapies, further fuels market expansion. Additionally, the demand for <strong>immunoglobulin treatments</strong> for neurological diseases is contributing to market growth.</p>
<h3>Market Segment Breakdown</h3>
<h4>By Application:</h4>
<ul data-spread="">
<li>
<p>Hypogammaglobulinemia</p>
</li>
<li>
<p>Chronic Inflammatory Demyelinating Polyneuropathy (<strong>CIDP</strong>)</p>
</li>
<li>
<p>Immunodeficiency Diseases</p>
</li>
<li>
<p>Congenital <strong>AIDS</strong></p>
</li>
<li>
<p>Chronic Lymphocytic Leukemia</p>
</li>
<li>
<p>Myasthenia Gravis</p>
</li>
<li>
<p>Multifocal Motor Neuropathy</p>
</li>
<li>
<p>Immune Thrombocytopenic Purpura (<strong>ITP</strong>)</p>
</li>
<li>
<p>Kawasaki Disease</p>
</li>
<li>
<p>Guillain-Barr&eacute; Syndrome</p>
</li>
</ul>
<h4>By Distribution Channel:</h4>
<ul data-spread="">
<li>
<p><strong>Hospital Pharmacy</strong></p>
</li>
<li>
<p><strong>Specialty Pharmacy</strong></p>
</li>
</ul>
<h3>Top Performing Companies</h3>
<ul data-spread="">
<li>
<p><strong>Baxalta Incorporated</strong></p>
</li>
<li>
<p><strong>Biotest AG</strong></p>
</li>
<li>
<p><strong>China Biologic Products Inc.</strong></p>
</li>
<li>
<p><strong>CSL Behring LLC</strong></p>
</li>
<li>
<p><strong>Grifols S.A.</strong></p>
</li>
<li>
<p><strong>Kedrion S.p.A.</strong></p>
</li>
<li>
<p><strong>LFB Biomedicaments S.A.</strong></p>
</li>
<li>
<p><strong>Octapharma AG</strong></p>
</li>
<li>
<p><strong>Sanquin Plasma Products B.V.</strong></p>
</li>
<li>
<p><strong>Bharat Serums and Vaccines Limited</strong></p>
</li>
</ul>
<p><strong>Download Free Sample Report with&nbsp;Complimentary Analyst Consultation : <a href="https://straitsresearch.com/report/intravenous-immunoglobulin-market/request-sample">https://straitsresearch.com/report/intravenous-immunoglobulin-market/request-sample</a><br /></strong></p>
<h3>Emerging Prospects</h3>
<p>The market is expected to witness further growth with ongoing research into <strong>novel immunoglobulin therapies</strong> and increasing government initiatives to support plasma collection and immunoglobulin production. Advances in <strong>recombinant immunoglobulins</strong> and subcutaneous alternatives also provide promising opportunities.</p>
<h3>Industry Movements</h3>
<p>Several key industry movements are shaping the <strong>IVIG Market</strong>, including <strong>strategic acquisitions</strong>, <strong>collaborations</strong>, and <strong>expansion initiatives</strong> by major players. Increased investment in <strong>R&amp;D</strong>, particularly for treating neurological and autoimmune disorders, is enhancing the therapeutic landscape. Regulatory advancements are also facilitating quicker approval of <strong>IVIG products.</strong></p>
<h3>Geographic Analysis</h3>
<p>North America holds the largest market share due to <strong>well-established healthcare infrastructure</strong> and <strong>strong government support</strong> for immunoglobulin therapies. Europe follows closely with increasing awareness and adoption of <strong>plasma-derived products</strong>. The <strong>Asia-Pacific region</strong> is expected to witness the highest growth rate due to a <strong>rising prevalence of immunodeficiency diseases</strong> and expanding healthcare expenditure in countries such as <strong>China, India, and Japan</strong>.</p>
<h3>Data Insights</h3>
<p>The market's steady growth is supported by an <strong>increase in plasma collection centers</strong>, technological innovations, and improvements in <strong>cold chain logistics</strong> for the safe transportation of IVIG products. With the growing demand for <strong>personalized medicine</strong>, new formulations of <strong>IVIG therapy</strong> are likely to gain traction in the coming years.</p>
<h3>Contact Us</h3>
<p><strong>Email:</strong><a>sales@straitsresearch.com</a><br /><strong>Phone:</strong> +1 646 905 0080 (<strong>US</strong>), +91 8087085354 (<strong>India</strong>), +44 203 695 0070 (<strong>UK</strong>)</p>
